ADC Therapeutics/$ADCT
1D1W1MYTD1Y5YMAX
Capital at risk
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
- Ticker
- $ADCT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 191
- Headquarters
- Epalinges, Switzerland
- Website
- www.adctherapeutics.com
ADC Therapeutics Metrics
BasicAdvanced
$142M
-
-$0.65
1.85
-
Price and volume
Market cap
$142M
Beta
1.85
52-week high
$4.98
52-week low
$0.78
Average daily volume
1.6M
Financial strength
Current ratio
3.031
Quick ratio
2.863
Long term debt to equity
-1.801
Total debt to equity
-1.828
Interest coverage (TTM)
-1.80%
Profitability
EBITDA (TTM)
-94.207
Gross margin (TTM)
-11.59%
Net profit margin (TTM)
-121.77%
Operating margin (TTM)
-118.19%
Effective tax rate (TTM)
0.42%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-19.67%
Return on equity (TTM)
45.35%
Valuation
Price to revenue (TTM)
2.08
Price to book
-0.62
Price to tangible book (TTM)
-0.62
Price to free cash flow (TTM)
-1.618
Free cash flow yield (TTM)
-61.81%
Free cash flow per share (TTM)
-0.686
Growth
Revenue change (TTM)
3.03%
Earnings per share change (TTM)
-58.76%
3-year revenue growth (CAGR)
-24.43%
3-year earnings per share growth (CAGR)
-34.35%
What the Analysts think about ADC Therapeutics
Analyst ratings (Buy, Hold, Sell) for ADC Therapeutics stock.
Analyst projections of the future price of ADC Therapeutics stock.
ADC Therapeutics Financial Performance
Revenues and expenses
ADC Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
ADC Therapeutics News
AllArticlesVideos
Funds containing ADC Therapeutics
AllUSDEURGBP
Fund name | Fund size | $ADCT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.01% |
iShares Ageing Population€AGED | €822M | 0.01% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.01% |
iShares Healthcare Innovation£DRDR | £1B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.